Galapagos' TYK2 Inhibitor GLPG3667 Meets Primary Endpoint in Dermatomyositis Phase 3-Enabling Study
核心洞察
Galapagos' selective TYK2 (搜索) inhibitor GLPG3667 achieved statistical significance in its primary endpoint for dermatomyositis (搜索), demonstrating meaningful clinical benefit in the GALARISSO study.
The drug showed a statistically significant improvement in Total Improvement Score at Week 24 compared to placebo, with favorable safety profile observed throughout the 24-week treatment period.
In systemic lupus erythematosus (搜索), GLPG3667 did not meet its primary endpoint but showed numerical improvements on several secondary endpoints, particularly skin-related outcomes.
Galapagos announced positive topline results from its Phase 3-enabling GALARISSO study, where the selective TYK2 (搜索) inhibitor GLPG3667 met its primary endpoint in patients with dermatomyositis (搜索). The drug demonstrated statistically significant clinical benefit compared to placebo, marking a potential breakthrough for a rare autoimmune disease with limited treatment options.
Dermatomyositis Study Achieves Primary Endpoint
The GALARISSO study evaluated GLPG3667 150 mg once daily versus placebo in 40 adult patients with dermatomyositis (搜索) over 24 weeks. The drug achieved statistical significance in the primary endpoint of Total Improvement Score (TIS) at Week 24 (p=0.0848; Δ: 14.26) compared to placebo, meeting the pre-specified threshold of statistical significance set at 10% (α=0.1).
GLPG3667 also demonstrated meaningful clinical improvements on several secondary endpoints of disease activity, including TIS20, TIS40, TIS60, and Modified-Cutaneous Dermatomyositis (搜索) Disease Area and Severity Index Activity Score (m-CDASI-A). The drug maintained a favorable safety and tolerability profile throughout the treatment period.
"The results from the GALARISSO study demonstrate that GLPG3667 has the potential to become an important new treatment option for patients living with dermatomyositis (搜索), a debilitating autoimmune disease with limited therapeutic alternatives," said Prof. Dr. Rohit Aggarwal from the University of Pittsburgh Medical Center. "Furthermore, the improvements in patients' disease activity observed in the study are encouraging."
Mixed Results in Systemic Lupus Erythematosus
The concurrent GALACELA study in systemic lupus erythematosus (搜索) (SLE) yielded mixed results. GLPG3667, administered at 75 mg and 150 mg once daily doses in 186 patients, did not achieve statistical significance in the primary endpoint analysis of dose-response on SLE responder index (SRI)-4 at Week 32.
However, the drug showed numerical improvements over placebo on several secondary endpoints, particularly on skin-related outcomes. The safety profile remained consistent with previous GLPG3667 studies. The GALACELA study continues with final Week 48 data expected in the second quarter of 2026.
Addressing Significant Unmet Medical Need
Dermatomyositis (搜索) represents a substantial unmet medical need, with prevalence estimated at one to six per 100,000 adults in the United States. The disease is characterized by inflammatory and degenerative changes of muscles and skin, with patients experiencing severe muscle weakness, pain, and skin disease activity that significantly impairs quality of life.
The overall mortality ratio in dermatomyositis (搜索) patients remains three times higher compared to the general population, with cancer, lung, and cardiac complications and infections being the most common causes of death. Currently, only one treatment is approved for dermatomyositis, highlighting the critical need for alternative safe and effective treatment options.
Strategic Development Plans
Henry Gosebruch, CEO of Galapagos, emphasized the significance of the positive dermatomyositis (搜索) results: "The positive results from the GALARISSO study in patients with dermatomyositis further validate the anti-inflammatory potential of our selective TYK2 (搜索) inhibitor, consistent with findings from our earlier Phase 1b psoriasis study and supportive in vitro pharmacology."
The company is evaluating all strategic options to maximize program value, including resuming potential partnering discussions announced earlier this year to accelerate development in dermatomyositis (搜索) and exploring opportunities to expand into other severe autoimmune diseases with significant unmet medical need.
Gilead has agreed to temporarily waive certain rights under its 10-year global Option, License and Collaboration Agreement with Galapagos, enabling the company to pursue external partnership opportunities for GLPG3667.
Study Design and Mechanism
GLPG3667 is an investigational reversible and selective tyrosine kinase 2 (搜索) (TYK2 (搜索)) kinase domain inhibitor. The GALARISSO study was designed as a randomized, double-blind, placebo-controlled, multi-center proof-of-concept study with patients offered the possibility to enter a long-term extension study for an additional 24-week period.
The primary endpoint utilized the Total Improvement Score at Week 24 according to American College of Rheumatology and European League Against Rheumatism criteria. Secondary endpoints included proportion of patients achieving minimal improvement, changes in disease activity scores, and functional assessments.
Galapagos plans to present detailed data at an upcoming medical conference, providing the scientific community with comprehensive insights into GLPG3667's therapeutic potential in dermatomyositis (搜索) and its broader autoimmune disease applications.